Literature DB >> 20186995

Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction.

Min Liang1, Masakazu Kamata, Kevin N Chen, Nonia Pariente, Dong Sung An, Irvin S Y Chen.   

Abstract

BACKGROUND: We recently expressed a potent and noncytotoxic short hairpin (sh)RNA directed against chemokine (c-c motif) receptor 5 (CCR5) using lentiviral mediated transduction of CD34+ hematopoietic progenitor cells (HPCs) and demonstrated the stable reduction of CCR5 expression in T-lymphocytes.
METHODS: In the present study, we further assessed the activity of the shRNA through HPC transduction and differentiation into macrophages derived from fetal liver CD34+ (FL-CD34+) HPCs. Transduced lentiviral vector encoding the human CCR5 shRNA was stably maintained in FL-CD34+ cells and in the terminally differentiated macrophages using macrophage colony-stimulating factor, granulocyte macrophage colony-stimulating factor, interleukin-3 and stem cell factor.
RESULTS: Quantitative real-time polymerase chain reaction for CCR5 mRNA indicated over 90% reduction of CCR5 mRNA levels in CCR5 shRNA-transduced population. The cells with knockdown of CCR5 expression acquired resistance to R5 tropic HIV-1 NFN-SX strain. We also developed a novel approach utilizing a mCherry-CCR5 chimeric reporter to assess the effectiveness of CCR5 target down-regulation in macrophages directly. Both the shRNA and the reporter were maintained throughout HPC differentiation to macrophages without apparent cytotoxicity.
CONCLUSIONS: The present study demonstrates a novel method to simply and directly assess the function of small interfering RNA and the effective inhibition of HIV-1 infection by a potential potent shRNA to CCR5 delivered into macrophages derived from HPCs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20186995      PMCID: PMC4340654          DOI: 10.1002/jgm.1440

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  45 in total

1.  Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy.

Authors:  Ming-Jie Li; James Kim; Shirley Li; John Zaia; Jiing-Kuan Yee; Joseph Anderson; Ramesh Akkina; John J Rossi
Journal:  Mol Ther       Date:  2005-08-22       Impact factor: 11.454

2.  Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity.

Authors:  Aimee L Jackson; Julja Burchard; Janell Schelter; B Nelson Chau; Michele Cleary; Lee Lim; Peter S Linsley
Journal:  RNA       Date:  2006-05-08       Impact factor: 4.942

3.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

4.  Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection.

Authors:  M Zaitseva; A Blauvelt; S Lee; C K Lapham; V Klaus-Kovtun; H Mostowski; J Manischewitz; H Golding
Journal:  Nat Med       Date:  1997-12       Impact factor: 53.440

Review 5.  HIV-1 coreceptors and their inhibitors.

Authors:  N Ray; R W Doms
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

Review 6.  Chemokine antagonists as therapeutics: focus on HIV-1.

Authors:  Athe M N Tsibris; Daniel R Kuritzkes
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

7.  Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.

Authors:  M Núñez; R Lana; J L Mendoza; L Martín-Carbonero; V Soriano
Journal:  J Acquir Immune Defic Syndr       Date:  2001-08-15       Impact factor: 3.731

8.  siRNA-mediated gene silencing in vitro and in vivo.

Authors:  Haibin Xia; Qinwen Mao; Henry L Paulson; Beverly L Davidson
Journal:  Nat Biotechnol       Date:  2002-09-16       Impact factor: 54.908

9.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

10.  Predictors of disease progression in HIV infection: a review.

Authors:  Simone E Langford; Jintanat Ananworanich; David A Cooper
Journal:  AIDS Res Ther       Date:  2007-05-14       Impact factor: 2.250

View more
  30 in total

Review 1.  The use of cell-delivered gene therapy for the treatment of HIV/AIDS.

Authors:  Geoff P Symonds; Helen A Johnstone; Michelle L Millington; Maureen P Boyd; Bryan P Burke; Louis R Breton
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

Review 2.  Stem cell gene therapy for HIV: strategies to inhibit viral entry and replication.

Authors:  David L DiGiusto
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

3.  Ectopic expression of anti-HIV-1 shRNAs protects CD8(+) T cells modified with CD4ζ CAR from HIV-1 infection and alleviates impairment of cell proliferation.

Authors:  Masakazu Kamata; Patrick Y Kim; Hwee L Ng; Gene-Errol E Ringpis; Emiko Kranz; Joshua Chan; Sean O'Connor; Otto O Yang; Irvin S Y Chen
Journal:  Biochem Biophys Res Commun       Date:  2015-05-19       Impact factor: 3.575

4.  Generation of human induced pluripotent stem cells bearing an anti-HIV transgene by a lentiviral vector carrying an internal murine leukemia virus promoter.

Authors:  Masakazu Kamata; Shirley Liu; Min Liang; Yoshiko Nagaoka; Irvin S Y Chen
Journal:  Hum Gene Ther       Date:  2010-10-06       Impact factor: 5.695

Review 5.  Novel cell and gene therapies for HIV.

Authors:  James A Hoxie; Carl H June
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

Review 6.  Stem cell-based therapies for HIV/AIDS.

Authors:  Olivier Pernet; Swati Seth Yadav; Dong Sung An
Journal:  Adv Drug Deliv Rev       Date:  2016-05-02       Impact factor: 15.470

7.  Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection.

Authors:  Lin Ye; Jiaming Wang; Ashley I Beyer; Fernando Teque; Thomas J Cradick; Zhongxia Qi; Judy C Chang; Gang Bao; Marcus O Muench; Jingwei Yu; Jay A Levy; Yuet Wai Kan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-09       Impact factor: 11.205

Review 8.  Targeted DNA mutagenesis for the cure of chronic viral infections.

Authors:  Joshua T Schiffer; Martine Aubert; Nicholas D Weber; Esther Mintzer; Daniel Stone; Keith R Jerome
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

9.  Live cell monitoring of hiPSC generation and differentiation using differential expression of endogenous microRNAs.

Authors:  Masakazu Kamata; Min Liang; Shirley Liu; Yoshiko Nagaoka; Irvin S Y Chen
Journal:  PLoS One       Date:  2010-07-28       Impact factor: 3.240

Review 10.  Adoptive immunotherapy for cancer or viruses.

Authors:  Marcela V Maus; Joseph A Fraietta; Bruce L Levine; Michael Kalos; Yangbing Zhao; Carl H June
Journal:  Annu Rev Immunol       Date:  2014-01-09       Impact factor: 28.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.